{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:34:48Z","timestamp":1760888088630},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1007\/s11938-004-0021-5","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T15:26:14Z","timestamp":1180884374000},"page":"13-17","source":"Crossref","is-referenced-by-count":18,"title":["Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy"],"prefix":"10.1007","volume":"7","author":[{"given":"Robert G.","family":"Maki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"21_CR1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000478-198309000-00001","volume":"7","author":"MT Mazur","year":"1983","unstructured":"Mazur MT, Clark HB: Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983, 7:507\u2013519.","journal-title":"Am J Surg Pathol"},{"key":"21_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00125480-199901000-00003","volume":"6","author":"JK Chan","year":"1999","unstructured":"Chan JK: Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases? Adv Anatomy Pathol 1999, 6:19\u201340.","journal-title":"Adv Anatomy Pathol"},{"key":"21_CR3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577\u2013580.","journal-title":"Science"},{"key":"21_CR4","first-page":"728","volume":"11","author":"M Sarlomo-Rikala","year":"1998","unstructured":"Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M: CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998, 11:728\u2013734.","journal-title":"Mod Pathol"},{"key":"21_CR5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1081\/CNV-120002485","volume":"20","author":"JH Edmonson","year":"2002","unstructured":"Edmonson JH, Marks RS, Buckner JC, Mahoney MR: Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002, 20:605\u2013612.","journal-title":"Cancer Invest"},{"key":"21_CR6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0960-7404(00)00026-8","volume":"9","author":"FC Eilber","year":"2000","unstructured":"Eilber FC, Rosen G, Forscher C, et al.: Recurrent gastrointestinal stromal sarcomas. Surg Oncol 2000, 9:71\u201375.","journal-title":"Surg Oncol"},{"key":"21_CR7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0093-7754(01)90099-5","volume":"28","author":"GD Demetri","year":"2001","unstructured":"Demetri GD: Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001, 28:19\u201326.","journal-title":"Semin Oncol"},{"key":"21_CR8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Duensing A, et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708\u2013710. This paper is the first to describe a tyrosine kinase receptor pathway other than the KIT tyrosine kinase pathway that appears to be responsible for the generation of GISTs in a small percentage of patients with this diagnosis.","journal-title":"Science"},{"key":"21_CR9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/annonc\/mdf672","volume":"13","author":"I Judson","year":"2002","unstructured":"Judson I: Gastrointestinal stromal tumours (GIST): biology and treatment. Ann Oncol 2002, 13:287\u2013289.","journal-title":"Ann Oncol"},{"key":"21_CR10","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","volume":"358","author":"AT Oosterom van","year":"2001","unstructured":"van Oosterom AT, Judson I, Verweij J, et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421\u20131423. The first phase I study of imatinib in patients with GIST showed that the majority of patients achieved partial responses.","journal-title":"Lancet"},{"key":"21_CR11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472\u2013480. This study of 140 patients confirmed the high response rate to imatinib seen in the phase I study.","journal-title":"N Engl J Med"},{"key":"21_CR12","first-page":"3271","volume":"22","author":"RS Benjamin","year":"2003","unstructured":"Benjamin RS, Rankin C, Fletcher C, et al.: Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results [abstract]. Proc Am Soc Clin Oncol 2003, 22:3271. This represents the state of the art in GIST therapy. Two phase III studies prove the activity of imatinib at 400 mg\/d and show response rates are identical at 400 or 800 mg\/d. The analysis is preliminary, however.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"21_CR13","first-page":"3272","volume":"22","author":"J Verweij","year":"2003","unstructured":"Verweij J, Casali PG, Zalcberg J, et al.: Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG [abstract]. Proc Am Soc Clin Oncol 2003, 22:3272. The study was similar to the study by Benjamin et al. [12], but early results indicate that the higher dose (800 mg\/d) is favorable with respect to progression-free survival. It is also unclear if overall survival will turn out to be different. With time, the picture will become clearer.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"21_CR14","first-page":"3273","volume":"22","author":"GD Demetri","year":"2003","unstructured":"Demetri GD, George S, Heinrich MC, et al.: Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate [abstract]. Proc Am Soc Clin Oncol 2003, 22:3273. For those patients with progression on imatinib, SU11248 offers at least some evidence of activity in imatinib-refractory patients.","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-004-0021-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-004-0021-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-004-0021-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:56:59Z","timestamp":1559422619000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-004-0021-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["21"],"URL":"https:\/\/doi.org\/10.1007\/s11938-004-0021-5","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}